• A key CDC advisory panel has postponed a decision on potentially delaying the first hepatitis B vaccine dose for infants born to mothers who test negative for the virus.
  • Public health experts and advocacy groups warn the proposed change could reverse decades of progress, risking a resurgence of infant hepatitis B infections.
  • The delay centers on resolving insurance coverage discrepancies within the Vaccines for Children program, which serves low-income and uninsured populations.

A pivotal vote that could have altered a cornerstone of U.S. infant immunization policy has been put on hold. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has delayed its decision on whether to change the long-standing recommendation that all newborns receive their first hepatitis B vaccine dose within 24 hours of birth.

The committee’s deliberations focus on a proposal to postpone this initial shot for babies whose mothers test negative for hepatitis B, potentially moving it to the one-month pediatric visit. However, the vote was tabled to address significant logistical concerns, primarily around ensuring uninterrupted insurance coverage for all infants, according to people familiar with the matter.

The potential policy shift has ignited a fierce debate among infectious disease specialists. The current universal birth dose policy, implemented in 1991, is credited with reducing childhood hepatitis B cases by an estimated 99%. Altering it, experts from groups like the Hepatitis B Foundation argue, would create a dangerous loophole. They caution that infants could fall through the cracks if their mothers did not receive prenatal screening, if test results were misrecorded, or if a mother contracted the virus after her initial test.

“The system is not perfect,” one committee member noted during the discussions, highlighting the very real risk of missing vulnerable infants. The vaccine itself is highly effective, with a 94% success rate at preventing perinatal transmission when combined with hepatitis B immunoglobulin (HBIG), and safety data presented to the panel showed a very low risk of side effects from neonatal administration.

The economic implications are a central part of the debate. The decision is particularly consequential for the federally funded Vaccines for Children (VFC) program, which supplies vaccines for approximately half of the nation's children who are uninsured, Medicaid-eligible, or from other vulnerable groups. Any change in the official recommendation could create confusion and coverage gaps for providers and parents, though health insurance groups have reportedly committed to covering all previously recommended vaccines through next year.

The ACIP also recently decided to recommend splitting the measles, mumps, rubella, and varicella (MMRV) vaccine for children under four due to a minor increased seizure risk, demonstrating the panel's ongoing efforts to balance robust protection with the finest safety data. The situation remains fluid, and the committee is expected to revisit the hepatitis B birth dose recommendation once coverage pathway concerns are resolved.